Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
GATA2
REST API REST API
Homo sapiens
GATA2 is differentially expressed in 306 experiments: 122 organism parts: placenta, prostate, ... (120 more);, 189 disease states: normal, lung adenocarcinoma, ... (187 more);, 109 cell types 418 cell lines 32 compound treatments and 82 other conditions.
Synonyms NFE1B
Orthologs gata2b (Danio rerio)   GATA2_CHICK (Gallus gallus)   Gata2 (Rattus norvegicus)   GATA2 (Bos taurus)   Gata2 (Mus musculus)   gata2a (Danio rerio)   Q4H3F5_CIOIN (Ciona intestinalis)   DAL80 (Saccharomyces cerevisiae)   GAT1 (Saccharomyces cerevisiae)   GZF3 (Saccharomyces cerevisiae)   GLN3 (Saccharomyces cerevisiae)   grn (Drosophila melanogaster)   gata2 (Xenopus laevis)   GATA2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term neuron differentiation, DNA binding, protein binding, regulation of transcription, DNA-dependent, cell fate determination, protein complex, transcription, DNA-dependent, regulation of histone acetylation, metal ion binding, blood coagulation, transcription factor binding, cell differentiation, phagocytosis, sequence-specific DNA binding, positive regulation of transcription from RNA polymerase II promoter, negative regulation of Notch signaling pathway, nucleus, somatic stem cell maintenance, chromatin binding, central nervous system neuron development, nucleoplasm, negative regulation of transcription from RNA polymerase II promoter, zinc ion binding, pituitary gland development, positive regulation of erythrocyte differentiation, urogenital system development, definitive hemopoiesis, C2H2 zinc finger domain binding, negative regulation of myeloid cell differentiation, cell maturation, homeostasis of number of cells within a tissue, negative regulation of fat cell differentiation, cell differentiation in hindbrain, inner ear morphogenesis, neuron fate commitment, positive regulation of angiogenesis, negative regulation of macrophage differentiation, positive regulation of phagocytosis, positive regulation of megakaryocyte differentiation, embryonic placenta development, ventral spinal cord interneuron differentiation, semicircular canal development, sequence-specific DNA binding transcription factor activity, negative regulation of neural precursor cell proliferation, enhancer sequence-specific DNA binding, negative regulation of fat cell proliferation, RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription, eosinophil fate commitment, RNA polymerase II distal enhancer sequence-specific DNA binding
InterPro Term TF_GATA-1/2/3, Znf_GATA
UniProt Accession C9J965, P23769
Gene-Disease Assocation DENDRITIC CELL, MONOCYTE, B LYMPHOCYTE, AND NATURAL KILLER LYMPHOCYTE
Search EB-eye ENSG00000179348
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (48 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
K562
3
E-MTAB-37, E-GEOD-96, E-GEOD-24147
SW480
1
3
E-MEXP-1014, E-MTAB-37, E-GEOD-18005, E-GEOD-2509
DU145
2
E-GEOD-17482, E-GEOD-20089
HL-60
2
E-MTAB-37, E-GEOD-24147
LNCaP
2
E-GEOD-14990, E-GEOD-14464
412 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (55 experiments)

Factor Value U/D Experiments
endothelial cell
3
E-GEOD-3920, E-GEOD-19240, E-GEOD-96
CD34+
2
E-AFMX-5, E-TABM-145
macrophage
1
2
E-GEOD-3982, E-GEOD-360, E-GEOD-8286
hematopoietic progenitor cells
1
E-MEXP-70
epidermal keratinocyte
1
E-GEOD-2822
CD8+CD28+
1
E-MEXP-2345
103 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-TABM-15, E-MTAB-62, E-MTAB-680, ... (65 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-GEOD-2514, E-MEXP-231, E-MTAB-62, E-MTAB-37
chronic myelogenous leukemia
3
E-MTAB-37, E-MTAB-62, E-GEOD-5550
benign prostatic hyperplasia
2
E-MEXP-1243, E-GEOD-7307
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
choriocarcinoma
2
E-MTAB-37, E-MTAB-62
glioblastoma
2
E-MTAB-62, E-GEOD-6014
183 more value(s).


Compound treatment

studied in E-GEOD-4668, E-GEOD-6907, E-GEOD-15205, E-TABM-782, E-TABM-868, ... (21 experiments)

Factor Value U/D Experiments
glutamine
2
E-MEXP-1335, E-MEXP-941
lipopolysaccharide
2
E-GEOD-3982, E-TABM-868
none
5
6
E-TABM-868, E-GEOD-4600, E-GEOD-20719, E-GEOD-412, E-GEOD-4668, ... (11 experiments)
immunoglobulin E
1
E-GEOD-3982
TNF
1
E-GEOD-15205
unknown
1
E-GEOD-7307
26 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
LT6
1
1
E-GEOD-21521
not specified
1
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-21374, ... (8 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1638, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-TABM-147

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-MTAB-73, E-GEOD-20847, E-MTAB-108, E-GEOD-6431, ... (7 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-868, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-12773, E-GEOD-20504, E-MEXP-1446, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-1926, E-MEXP-2069, E-GEOD-19136, ... (31 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-1493, E-GEOD-22309, E-GEOD-21750, E-MEXP-1412, ... (9 experiments)

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-18791

RNAi
studied in E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-1315, E-MEXP-2759 ... (5 experiments)

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-18995

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Stimulus or stress
studied in E-GEOD-7538

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Tissue
studied in E-GEOD-30573

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561, E-TABM-147

Vehicle
studied in E-GEOD-5258

Processing time: 0.346 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM